USPTO granted Lundbeck A/S Patent No. US12590106B2 on March 31, 2026, for spiromacrocyclic orexin 2 receptor agonist compounds of general formula (I) used in CNS therapeutic applications. The patent contains 18 claims and lists CPC classifications spanning C07D 498/14, A61K 31/424, and related pharmaceutical composition categories. The invention relates to novel spiro-macrocyclic compounds acting as Orexin 2 receptor agonists.

Pharmaceutical companies and drug manufacturers developing orexin 2 receptor modulators or CNS therapeutics should conduct freedom-to-operate analyses to assess potential patent infringement risks. Competitors working in the orexin pathway space should evaluate whether Lundbeck's patent scope covers their compound structures and consider whether to pursue licensing, design-around strategies, or invalidation proceedings if relevant to their pipeline.